Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 41
2004 55
2005 126
2006 166
2007 224
2008 285
2009 342
2010 375
2011 434
2012 512
2013 520
2014 509
2015 527
2016 574
2017 595
2018 569
2019 275
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

5,136 results
Results by year
Filters applied: . Clear all
Page 1
SB5: An Adalimumab Biosimilar.
Frampton JE. BioDrugs 2018 - Review. PMID 30251234
The safety and tolerability profile of SB5 was similar to that of reference adalimumab, as was the immunogenicity profile. Switching from reference adalimumab to SB5 had no impact in terms of efficacy, safety or immunogenicity. The role of reference adalimumab in the management of RA, pJIA, ERA, AS, nr-axSpA, PsA, psoriasis, pediatric plaque psoriasis, HS, Crohn's disease, UC and non-infectious uveitis is well established and SB5 provides an effective biosimilar alternative for patients requiring adalimumab therapy....
The safety and tolerability profile of SB5 was similar to that of reference adalimumab, as was the immunogenicity profile. Switching …
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, et al. N Engl J Med 2019 - Clinical Trial. PMID 31553834
RESULTS: A total of 769 patients underwent randomization and received at least one dose of vedolizumab (383 patients) or adalimumab (386 patients). ...Corticosteroid-free clinical remission occurred in 12.6% of the patients in the vedolizumab group and in 21.8% in the adalimumab group (difference, -9.3 percentage points; 95% CI, -18.9 to 0.4). ...
RESULTS: A total of 769 patients underwent randomization and received at least one dose of vedolizumab (383 patients) or adalimumab ( …
GP2017: An Adalimumab Biosimilar.
Heo YA. BioDrugs 2018 - Review. PMID 30460599
GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved. ...The role of reference adalimumab in the management of autoimmune inflammatory conditions is well established and GP2017 provides an effective biosimilar alternative for patients requiring adalimumab therapy....
GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference a
FKB327: An Adalimumab Biosimilar.
Al-Salama ZT. BioDrugs 2019 - Review. PMID 30712241
FKB327 (Hulio(®)) is a biosimilar of the reference monoclonal anti-TNFα antibody adalimumab, and is approved in the EU for use in the same indications as reference adalimumab. ...Switching from reference adalimumab to FKB327 had no impact on efficacy, safety or immunogenicity....
FKB327 (Hulio(®)) is a biosimilar of the reference monoclonal anti-TNFα antibody adalimumab, and is approved in the EU for use in the …
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S, et al. BioDrugs 2019 - Review. PMID 31111422
However, adalimumab is likely to present unique challenges given the numbers of patients treated and the range of biosimilar adalimumab products available. ...The authors also discuss clinical data available so far on adalimumab biosimilars and their envisaged impact in the field of immune-mediated inflammatory diseases....
However, adalimumab is likely to present unique challenges given the numbers of patients treated and the range of biosimilar adali
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P, et al. JAMA Dermatol 2018 - Clinical Trial. PMID 29799960 Free PMC article.
Guselkumab was superior to placebo based on the proportion of patients achieving an ss-IGA score of 0 or 1 (560 [81.8%] vs 43 [12.4%]) at week 16 and to adalimumab (582 [85.0%] vs 329 [68.5%]) at week 24 (both P < .001); 479 (69.9%) in the guselkumab group vs 270 (56.3%) in the adalimumab group achieved an ss-IGA score of 0 (all P < .001). An hf-PGA score of 0 or 1 was achieved by 154 patients (75.5%) in the guselkumab group vs 15 (14.2%) in the placebo group at week 16 and 164 (80.4%) in the guselkumab group vs 91 (60.3%) in the adalimumab group at week 24; 153 (75.0%) in the guselkumab group vs 76 (50.3%) in the adalimumab group achieved an hf-PGA score of 0 (all P < .001). ...
Guselkumab was superior to placebo based on the proportion of patients achieving an ss-IGA score of 0 or 1 (560 [81.8%] vs 43 [12.4%]) at we …
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S, et al. Curr Rheumatol Rep 2018 - Review. PMID 30094742 Free PMC article.
PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. ...The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. ...
PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of num …
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K, et al. Lancet 2019 - Clinical Trial. PMID 31280967
For weeks 16-44 (part B), adalimumab intermediate responders were re-randomised 1:1 to continue 40 mg adalimumab or switch to 150 mg risankizumab. ...Adverse events were reported in 168 (56%) of 301 patients given risankizumab and 179 (57%) of 304 patients given adalimumab in part A, and among adalimumab intermediate responders, adverse events were reported in 40 (75%) of 53 patients who switched to risankizumab and 37 (66%) of 56 patients who continued adalimumab in part B. ...
For weeks 16-44 (part B), adalimumab intermediate responders were re-randomised 1:1 to continue 40 mg adalimumab or switch to …
5,136 results
Jump to page
Feedback